This review is a summary of evidence in support of enzalutamide use in patients with metastatic castration-resistant prostate cancer (mCRPC).
Independent commentary has been provided by Associate Professor Declan Murphy, Dr Shankar Siva and Dr Laurence Krieger
Please login below to download this issue (PDF)